Compare Medtronic PLC (MDT) vs Phillips 66 (PSX) Price & Performance

Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.

MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.

Phillips 66 (PSX) trades at $271.62, up 0.68% with a bullish technical outlook near its 52-week high. The stock shows strong profitability with 24.02% ROE and 4.66% net margin, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI implementation for operational efficiency. Current valuation metrics include a P/E of 16.07 and P/S of 0.75, suggesting reasonable pricing relative to peers.

PSX presents a compelling investment case with analyst consensus at Buy (54% rating) and $279 price target, though revenue declines from 2022-2025 pose concerns. Key risks include diesel export policy uncertainty and refining margin volatility. The company's debt reduction progress and projected 2026 earnings recovery to $7.1B support upside potential if operational execution continues.